--- title: "Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX" type: "News" locale: "en" url: "https://longbridge.com/en/news/295219705.md" description: "On August 7, 2026, several biotech stocks hit 52-week highs driven by positive catalysts. Delcath Systems (DCTH) surged 22% on strong Q2 revenues. Alto Neuroscience (ANRO), Hemab Therapeutics (COAG), Monopar Therapeutics (MNPR), and Nurix Therapeutics (NRIX) also reached new highs following positive trial data, funding announcements, or milestone payments." datetime: "2026-08-07T10:33:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295219705.md) - [en](https://longbridge.com/en/news/295219705.md) - [zh-HK](https://longbridge.com/zh-HK/news/295219705.md) generator: "portal-rs" --- # Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX Add as your preferred news source on Google Add Now The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation. **Delcath Systems Inc. (DCTH)** Delcath Systems is an interventional oncology company focused on developing therapies for primary and metastatic cancers. Shares shot up over 22% in Thursday's trade to reach $15.62, a new 52-week high. Delcath markets the *HEPZATO KIT* and CHEMOSTAT hepatic drug delivery system to administer chemotherapeutics directly to the liver. Second quarter results were released on Thursday, and the company recorded net revenues of $29.1 million, compared to $24.2 million in the previous year. Product revenue from HEPZATO grew about 30% to $27.1 million, and that from CHEMOSTAT was $2 million. The systems were utilized in about 31 active treatment centers. **Alto Neuroscience Inc. (ANRO)** Alto Neuroscience is a clinical-stage biopharmaceutical company advancing several precision therapies for neuropsychiatric disorders. The company saw shares rise to a 52-week high of $29.48 on Thursday. The company's lead drug candidates are ALTO-207 for treatment-resistant depression (TRD) and ALTO-300 for major depressive disorder (MDD), both of which are under a Phase 2 evaluation to confirm efficacy in biomarker positive patients. Further drugs in the pipeline include ALTO-100 for bipolar depression and ALTO-101 for schizophrenia, in addition to ALTO-203 and ALTO-202 for MDD. Last month, the company completed a registered direct offering with gross proceeds estimated at $100 million. The proceeds are expected to be used in developing ALTO-207, and for accelerating the drug towards a Phase 3 trial. **Hemab Therapeutics Holdings Inc. (COAG)** Hemab Therapeutics is a clinical-stage biotechnology company specializing in the development of therapies for blood coagulation disorders. Shares hit a 52-week high of $53.60 in intraday trading on Thursday. Last month, the company reported positive data from the Phase 2 LTE trial assessing Sutacimig for treating Glanzmann thrombasthenia and Factor VIII deficiency. The results indicated that the mean annualized treated bleeding rate (ATBR) reduced by 84%, and the participants who underwent surgical procedures reported positive hemostatic outcomes. The company also recently reported positive interim Phase 2 results for drug candidate HMB-002 in treating Von Willebrand's disease, and launched HMB-003, a new drug candidate for the treatment of heavy menstrual bleeding. **Monopar Therapeutics Inc. (MNPR)** Monopar Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing therapies for rare diseases and certain cancers. The company's stock reached a 52-week high of $124.31 in share price on Thursday. In June, the company released positive Phase 3 results for ALXN1840 in the treatment of Wilson disease, for which it has received a Rare Pediatric Disease voucher from the U.S. Food and Drug Administration (FDA). A new drug application (NDA) for ALXN1840 is planned for submission by mid-2026. Additionally, the company is advancing MNPR-101, a targeted antibody platform currently in Phase 1 development for radiopharmaceutical imaging and treatment of solid tumors. **Nurix Therapeutics Inc. (NRIX)** Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the development and manufacture of small molecule and antibody therapies for inflammatory diseases and cancer. Shares reached a 52-week high of $25.49 on Thursday. A milestone payment of $10 million was granted to the company by its collaborator Sanofi following the initiation of a Phase 1 trial for NX-3911, an oral STAT6 degrader against an undisclosed immunological target. The company, alongside Roche, reported on Tuesday the enrollment of the first patient in the Phase 3 DAYBreak CLL-306 trial evaluating Bexobrutideg in treating relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Nurix is further exploring the use of bexobrutideg in a Phase 1a/1b trial for relapsed/refractory B cell malignancies, and in combination with venetoclenax for treatment-naive CLL patients. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [MNPR.US](https://longbridge.com/en/quote/MNPR.US.md) - [ANRO.US](https://longbridge.com/en/quote/ANRO.US.md) - [NRIX.US](https://longbridge.com/en/quote/NRIX.US.md) - [COAG.US](https://longbridge.com/en/quote/COAG.US.md) - [DCTH.US](https://longbridge.com/en/quote/DCTH.US.md) - [SNY.US](https://longbridge.com/en/quote/SNY.US.md) - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) - [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md) - [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md) ## Related News & Research - [Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares](https://longbridge.com/en/news/297238555.md) - [Hemab Advances Bleeding Disorder Pipeline](https://longbridge.com/en/news/292520096.md) - [IRLAB Publishes Interim Report for The Period January - June 2026](https://longbridge.com/en/news/296991137.md) - [Global Brain leads investment in cancer detection startup MiRNDa](https://longbridge.com/en/news/296842692.md) - [JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis | ROIV Stock News](https://longbridge.com/en/news/297068196.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**